MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX) Stock Analysis — Latest Investor Quotes & Trade Calls

Avoid Long Position in MLTX

-34.46%current return

"MLTX big disappointment 88%. We didn't have the confidence uh either way of position like most of the street. I was thinking it maybe was long. It was not a long."

The speaker expresses strong disappointment with MLTX citing an '88% big disappointment' and explicitly rejects taking a long position on the stock, suggesting caution to investors.